| Literature DB >> 35236319 |
Ronelle Burger1, Timothy Köhler2, Aleksandra M Golos3, Alison M Buttenheim4, René English5, Michele Tameris6, Brendan Maughan-Brown7.
Abstract
BACKGROUND: COVID-19 vaccine hesitancy has threatened the ability of many countries worldwide to contain the pandemic. Given the severe impact of the pandemic in South Africa and disruptions to the roll-out of the vaccine in early 2021, slower-than-expected uptake is a pressing public health challenge in the country. We examined longitudinal changes in COVID-19 vaccination intent among South African adults, as well as determinants of intent to receive a vaccine.Entities:
Keywords: COVID-19 vaccine; Panel survey; South Africa; Vaccine acceptance; Vaccine hesitancy
Mesh:
Substances:
Year: 2022 PMID: 35236319 PMCID: PMC8889513 DOI: 10.1186/s12889-022-12826-5
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Fig. 1Timing of the NIDS-CRAM waves with respect to COVID-19 cases and lockdown levels in South Africa. Authors’ own arrangement. Source of COVID-19 case data: Our World in Data [8]. Solid line represents 7-day rolling average of daily new confirmed COVID-19 cases. L = lockdown level
Fig. 2Timeline of NIDS-CRAM survey dates, vaccine-related events, and administered doses in South Africa. Authors’ own arrangement. Source of vaccine dose data: Our World in Data [8]
Sample characteristics, NIDS-CRAM Waves 4 and 5
| Wave 4 | Wave 5 | Wave 4/5, Balanced Panel | ||||
|---|---|---|---|---|---|---|
| n | Weighted % | n | Weighted % | n | Weighted % | |
| Male | 2156 | 48 | 2248 | 48 | 1875 | 49 |
| Female | 3473 | 52 | 3614 | 52 | 3074 | 51 |
| 18–24 | 864 | 15 | 846 | 14 | 717 | 15 |
| 25–59 | 3920 | 70 | 4136 | 71 | 3494 | 71 |
| 60+ | 845 | 15 | 880 | 15 | 738 | 14 |
| African/ Black | 4896 | 79 | 5072 | 79 | 4298 | 70 |
| Coloured | 440 | 10 | 490 | 10 | 395 | 10 |
| Indian/ Asian | 43 | 2 | 46 | 2 | 39 | 2 |
| White | 250 | 9 | 254 | 9 | 217 | 9 |
| Up to primary | 1007 | 14 | 1037 | 14 | 879 | 14 |
| Up to secondary | 2138 | 36 | 2214 | 36 | 1870 | 36 |
| Completed secondary | 1293 | 22 | 1338 | 22 | 1149 | 22 |
| Tertiary | 1147 | 28 | 1224 | 28 | 1014 | 28 |
| Rural | 1684 | 24 | 1708 | 24 | 1464 | 24 |
| Urban | 3693 | 76 | 3855 | 76 | 3253 | 76 |
| No | 3673 | 81 | 3862 | 81 | 3215 | 81 |
| Yes | 1103 | 19 | 1116 | 19 | 974 | 19 |
| 1 | 1261 | 21 | 1459 | 20 | 1236 | 21 |
| 2 | 1355 | 19 | 1147 | 22 | 977 | 19 |
| 3 | 1150 | 20 | 1181 | 20 | 1015 | 20 |
| 4 | 876 | 21 | 1075 | 18 | 897 | 21 |
| 5 | 642 | 18 | 605 | 20 | 503 | 19 |
Note: Authors’ own calculations. Source: NIDS-CRAM Waves 4 and 5. Relevant estimates weighted using sampling weights
Fig. 3Self-reported intent to receive a COVID-19 vaccine, NIDS-CRAM Waves 4 and 5. Authors’ own calculations. Source: NIDS-CRAM Waves 4 and 5. Relevant estimates weighted using sampling weights
Individual-level changes in willingness to receive a COVID-19 vaccine between Waves 4 and 5
| Willing to receive, Wave 5 | |||||||
|---|---|---|---|---|---|---|---|
| Strongly Agree | Some-what Agree | Don’t Know | Some-what Disagree | Strongly Disagree | Already Vaccinated | Total | |
| | 45.99 | 2.18 | 0.78 | 1.49 | 2.49 | 0.92 | |
| | 9.05 | 4.37 | 0.38 | 1.25 | 1.68 | 0.25 | |
| | 3.08 | 0.53 | 1.28 | 0.17 | 0.79 | 0.02 | |
| | 2.14 | 1.20 | 0.57 | 1.55 | 2.37 | 0.02 | |
| | 4.61 | 1.58 | 0.40 | 1.75 | 6.63 | 0.47 | |
| | |||||||
Note: Authors’ own calculations. Source: NIDS-CRAM Waves 4 and 5. Relevant estimates weighted using sampling weights. The sample was restricted to the balanced panel of respondents who were in both Wave 4 and Wave 5 (n = 4931)
Individual-level distribution of willingness to receive a COVID-19 vaccine in Wave 5, based on willingness in Wave 4
| Willing to receive, Wave 5 | |||||||
|---|---|---|---|---|---|---|---|
| Strongly Agree (64.87) | Some what Agree (9.86) | Don’t Know (3.41) | Some what Disagree (6.21) | Strongly Disagree (13.96) | Already Vaccinated (1.69) | Total | |
| | 85.40 | 4.05 | 1.46 | 2.76 | 4.61 | 1.72 | |
| | 53.30 | 25.74 | 2.22 | 7.36 | 9.88 | 1.50 | |
| | 52.39 | 9.07 | 21.80 | 2.89 | 13.45 | 0.40 | |
| | 27.28 | 15.28 | 7.22 | 19.80 | 30.17 | 0.25 | |
| | 29.85 | 10.21 | 2.61 | 11.32 | 42.95 | 3.06 | |
Note: Authors’ own calculations. Source: NIDS-CRAM Waves 4 and 5. Relevant estimates weighted using sampling weights. The sample was restricted to the balanced panel of respondents who were in both Wave 4 and Wave 5 (n = 4931). Values in headings indicate the proportion of the sample that provided each response option
Reasons for vaccine safety concerns and strength of beliefs (subsample of respondents who believed that the vaccine was unsafe)
| Reason for concern about vaccine safety | % of subsample reporting reason | % of full sample reporting reason | % of subsample “very convinced” that the vaccine was unsafe |
|---|---|---|---|
| Vaccine testing rushed | 32 | 6 | 65 |
| Side effects | 20 | 4 | 53 |
| General safety concerns | 12 | 2 | 61 |
| Don’t trust | 10 | 2 | 42 |
| Vaccine government plot | 6 | 1 | 54 |
| Vaccine global plot | 6 | 1 | 35 |
| Ineffective | 4 | 1 | 39 |
| Vaccine will change DNA | 4 | 1 | 52 |
| Lack of information or knowledge | 3 | 1 | 48 |
| Vaccine fake for profit | 2 | < 1 | 51 |
| Other | 2 | < 1 | 47 |
| Wait and see | 2 | < 1 | 44 |
Note: Authors’ own calculations. Source: NIDS-CRAM Wave 5. Relevant estimates weighted using sampling weights